Srpk1 inhibitors
AssigneeExonate Limited
InventorsAndrew Douglas Baxter, Jonathan Morris, Andrew David Morley
Life of this patent
Estimating the term…
Abstract
Anti-angiogenic treatments, for example treatment of ocular neovascularization or cancer, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of treating or preventing fibrosis and compounds for use in such methods are described.
Claims21
-23. (canceled)
A compound of Formula (I):
- or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof;
- wherein:
- n=1, 2 or 3;
- R1 is halogen, difluoromethyl, trifluoromethyl, cyclopropyl, methyl, methoxy or trifluoromethoxy;
- R2 is furanyl, optionally having a 4-tetrahydropyranyl or 4-pyridyl substituent, or 2-pyridyl;
- R3 is hydroxyl, hydroxymethyl, methoxy, C1-C3 alkyl, carboxy, —C(O)NR5R6 or CH2NR5R6;
- R4 is hydrogen, methyl, ethyl, cyclopropyl, phenyl, benzyl or cyclopropylmethyl;
- or
- R3 and R4 together with the adjacent carbon atom form a 3- to 6-membered carbocycle or heterocycle;
- and
- R5 and R6 are independently selected from hydrogen, methyl, ethyl or propyl;
- or
- R5 and R6 are joined together to form a nitrogen-containing heterocycle.
-28. (canceled)
-38. (canceled)
-44. (canceled)
The method of claim 43, wherein the treatment is a dose-dependent treatment and/or a topical treatment.
The method of claim 43, wherein treatment of ocular neovascularisation comprises treatment of age related macular degeneration or macular oedema.
Dependencies are inferred from the claim text.